# Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

> **NCT02440464** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **PROCEDURE:** Allogeneic HSCT
- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Bortezomib
- **DRUG:** Ixazomib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02440464
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440464, "Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02440464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*